Literature DB >> 24120999

Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.

Ferran Roses-Noguer1, Julian W E Jarman1, Jonathan R Clague1, Jan Till2.   

Abstract

BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by adrenergically induced ventricular arrhythmias in patients with structurally normal hearts. Initiating triggered arrhythmias, such as bidirectional ventricular tachycardia, often degenerate into reentrant arrhythmias, such as ventricular fibrillation (VF).
OBJECTIVE: To determine whether the effectiveness of implantable cardioverter-defibrillator (ICD) shocks is dependent on rhythm type.
METHODS: It is a retrospective study of patients with CPVT who had undergone ICD implantation. Thirteen patients received ICDs (median age 15 years; range 9-43 years): 7 of 13 (54%) for cardiac arrest and 6 of 13 (46%) for syncope despite drug therapy. The median follow-up duration was 4.0 years (range 1.7-19.9 years). Nineteen reinterventions occurred, excluding generator replacements. Ten patients received 96 shocks (median 4 shocks; range 1-30 shocks). Eighty-seven shock electrograms were reviewed. Sixty-three (72%) shocks were appropriate, and 24 (28%) were inappropriate (T-wave oversensing 7 [29%], supraventricular arrhythmia 16 [67%], after self-terminating VF 1 [4%]).
RESULTS: Among appropriate shocks, 20 (32%) were effective in terminating sustained arrhythmia and 43 (68%) were ineffective. Shocks delivered to triggered arrhythmias nearly always failed (1 of 40 [3%] effective), while shocks delivered to VF were usually successful (19 of 23 [83%] effective; P < .001). Four patients received 17 appropriate antitachycardia pacing therapies for ventricular tachycardia: only 2 (12%) were effective. No patient died.
CONCLUSIONS: The effectiveness of ICD shock therapy in CPVT depends on the mechanism of the rhythm treated. Shocks delivered to initiating triggered arrhythmias nearly always fail, whereas those for subsequent VF are usually effective. ICD programming in these patients is exceptionally challenging.
© 2013 Published by Heart Rhythm Society on behalf of Heart Rhythm Society.

Entities:  

Keywords:  ATP; CI; CPVT; Catecholaminergic polymorphic ventricular tachycardia; ECG; ETT; ICD; Implantable cardioverter-defibrillator; LCSD; MVT; PVT; Pediatric; RGPVA; S-ICD; Sudden cardiac death; VF; VT; antitachycardia pacing; catecholaminergic polymorphic ventricular tachycardia; confidence interval; electrocardiogram; exercise tolerance test; implantable cardioverter-defibrillator; left cardiac sympathetic denervation; monomorphic ventricular tachycardia; polymorphic ventricular tachycardia; repeated grouped polymorphic ventricular activity; subcutaneous implantable cardioverter-defibrillator; ventricular fibrillation; ventricular tachycardia

Mesh:

Year:  2013        PMID: 24120999     DOI: 10.1016/j.hrthm.2013.10.027

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  24 in total

Review 1.  [Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies].

Authors:  D Duncker; T König; S Hohmann; C Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-22

Review 2.  Management of survivors of cardiac arrest - the importance of genetic investigation.

Authors:  Peter J Schwartz; Federica Dagradi
Journal:  Nat Rev Cardiol       Date:  2016-07-07       Impact factor: 32.419

3.  The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia.

Authors:  Krystien Vv Lieve; Arthur A Wilde; Christian van der Werf
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

Review 4.  Cardiac sympathetic denervation to prevent life-threatening arrhythmias.

Authors:  Peter J Schwartz
Journal:  Nat Rev Cardiol       Date:  2014-03-11       Impact factor: 32.419

Review 5.  Pregnancy in catecholaminergic polymorphic ventricular tachycardia: therapeutic optimization and multidisciplinary care are key to success.

Authors:  Thomas M Roston; Jasmine Grewal; Andrew D Krahn
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-04-21

6.  Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.

Authors:  Thomas M Roston; Jeffrey M Vinocur; Kathleen R Maginot; Saira Mohammed; Jack C Salerno; Susan P Etheridge; Mitchell Cohen; Robert M Hamilton; Andreas Pflaumer; Ronald J Kanter; James E Potts; Martin J LaPage; Kathryn K Collins; Roman A Gebauer; Joel D Temple; Anjan S Batra; Christopher Erickson; Maria Miszczak-Knecht; Peter Kubuš; Yaniv Bar-Cohen; Michal Kantoch; Vincent C Thomas; Gabriele Hessling; Chris Anderson; Ming-Lon Young; Michel Cabrera Ortega; Yung R Lau; Christopher L Johnsrude; Anne Fournier; Prince J Kannankeril; Shubhayan Sanatani
Journal:  Circ Arrhythm Electrophysiol       Date:  2015-02-24

7.  Left cardiac sympathetic denervation: case series and technical report.

Authors:  C McNamara; P Cullen; M Rackauskas; R Kelly; K E O'Sullivan; J Galvin; D Eaton
Journal:  Ir J Med Sci       Date:  2017-02-25       Impact factor: 1.568

Review 8.  Optimal tachycardia programming in ICDs : Recommendations in the post-MADIT-RIT era.

Authors:  Carsten W Israel; Tatsiana Burmistrava
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-09

Review 9.  Inherited cardiac arrhythmias.

Authors:  Peter J Schwartz; Michael J Ackerman; Charles Antzelevitch; Connie R Bezzina; Martin Borggrefe; Bettina F Cuneo; Arthur A M Wilde
Journal:  Nat Rev Dis Primers       Date:  2020-07-16       Impact factor: 52.329

10.  Gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Roger J Hajjar; Alexander R Lyon
Journal:  Circulation       Date:  2014-06-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.